Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig - bosutinib (bħala monoidrat) - lewkimja, myeloid - antineoplastic agents, protein kinase inhibitors - bosulif huwa indikat għat-trattament ta ' pazjenti adulti:għadhom kif ġew dijanjostikati fażi l-kronika (pk) philadelphia chromosome pożittivi għall-lewkimja tal-mudullun kronika (ph+ cml). cp, fil-fażi aċċelerata (ap), u blast phase (bp) ph+ cml li kienu kkurati qabel b'wieħed jew aktar ta 'tyrosine kinase(i) [tki(i)] u li għalihom imatinib, nilotinib u l-dasatinib ma huma kkunsidrati għażliet ta' trattament adattati.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - guanfacine hydrochloride - tnaqqis tad-defiċit ta 'l-attenzjoni b'hérapectivity - antiadrenergic agents, centrally acting, antihypertensives, - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. intuniv għandhom ikunu użati bħala parti minn komprensiva adhd-programm tat-trattament, tipikament inkluż psikoloġiċi, l-edukazzjoni u l-miżuri soċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - linagliptin, metformin - diabetes mellitus, tip 2 - drogi użati fid-dijabete - it-trattament ta 'pazjenti adulti b'dijabete tat-tip 2 mellitus:jentadueto huwa indikat bħala żieda mad-dieta u l-eżerċizzju biex itejjeb il-kontroll gliċemiku f'pazjenti adulti mhux ikkontrollati adegwatament fuq id-doża massima ttollerata ta' metformin waħdu jew għal dawk li diġà qegħdin jiġu kkurati b'kumbinazzjoni ta linagliptin u metformin. jentadueto huwa indikata f'kumbinazzjoni ma ' sulphonylurea (i. terapija ta 'kumbinazzjoni tripla) bħala żieda mad-dieta u l-eżerċizzju f'pazjenti adulti mhux ikkontrollati adegwatament fuq id-doża massima ttollerata ta' metformin u sulphonylurea.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - tolvaptan - kliewi poliċistiku, autosomal dominanti - id-dijuretiċi, - jinarc huwa indikat biex tnaqqas il-progressjoni tal-iżvilupp tal-Ġlata u insuffiċjenza renali tal-marda tal-kliewi polycystic dominanti autosomal (adpkd) fl-adulti b ' ckd stadju 1 sa 3 fil-bidu tat-trattament bi prova tal-marda malajr jipprogressa b ' mod.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

boehringer ingelheim - empagliflozin, metformin - diabetes mellitus, tip 2 - drogi użati fid-dijabete - synjardy huwa indikat f'adulti ta '18-il sena u akbar b'dijabete mellitus tip 2 bħala żieda mad-dieta u l-eżerċizzju biex itejjeb il-kontroll gliċemiku f'pazjenti mhux ikkontrollati adegwatament fuq l-ogħla doża ttollerata ta' metformin waħdu;f'pazjenti li mhumiex ikkontrollati biżżejjed bil-metformina flimkien ma'l-oħra tal-glukożju il-prodotti mediċinali li jbaxxu, inkluża l-insulina;fil-pazjenti li diġà qegħdin jiġu kkurati b'kumbinazzjoni ta empagliflozin u metformin bħala pilloli separati.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - diabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - neoplażmi tas-sider - terapija endokrinali - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - tacrolimus - rifjut ta 'graft - immunosoppressanti - profilassi tar-rifjut tat-trapjanti f'riċevituri ta 'l-alloġib tal-kliewi jew tal-fwied adulti. kura ta 'rifjut tal-allograft reżistenti għat-trattament ma' prodotti mediċinali immunosoppressivi oħra f'pazjenti adulti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astellas pharma europe b.v. - tacrolimus - rifjut ta 'graft - immunosoppressanti - profilassi tar-rifjut tat-trapjant f'reċipjenti adulti u pedjatriċi, tal-kliewi, tal-fwied jew tal-alloġib tal-qalb. it-trattament tal-allograft rifjut reżistenti għall-kura bi prodotti mediċinali immunosuppressivi oħra f'pazjenti adulti u pedjatriċi.